Recruiting

Balloon Pulmonary Angioplasty

Sponsor:

Jewish General Hospital

Code:

NCT05719415

Conditions

Hypertension, Pulmonary

Pulmonary Thromboembolisms

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Measurement of pulmonary functional capillary surface area

Study Details

Brief summary:

Chronic thromboembolic pulmonary hypertension \[CTEPH\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \[BPA\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \[FCSA\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.

Conditions

Hypertension, Pulmonary

Pulmonary Thromboembolisms

Study ID

NCT05719415

Start date

Mar 23, 2023

Status verified date

Sep, 2025

Completion date

Jan 30, 2028

Anticipated

Primary completion date

Jan 30, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension

Exclusion Criteria:

  • Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,
  • Presence of patent foramen ovale

Study Design

Enrollment

40 participants

Anticipated

Intervention Model

Single group

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Pre and post BPA

Interventions

Measurement of pulmonary functional capillary surface area

Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro

Primary outcome measure

  • Change in pulmonary functional capillary surface area [ Time Frame: 4 hours ]

Central Contacts and Locations

Central contacts

David Langleben, MD

5143407531david.langleben@mcgill.ca

Lyda Lesenko, MD

514-340-8222llesenko@jgh.mcgill.ca

Locations

David Langleben

Recruiting

Montreal, Quebec, Canada, H3W 2C4

Contacts

David Langleben

5143407531david.langleben@mcgill.ca

Principal Investigator:

David Langleben, MD

More Information

Sponsor

Jewish General Hospital

Last update posted

Sep 23, 2025

Last verified

Sep, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Jewish General Hospital on 2025-09-23.